Table 1.
Baseline characteristics in the treatment and placebo groups (prior to treatment start).
| Characteristic | N | Treatment N = 84 (54%) |
Placebo N = 71 (46%) |
p-Value | q-Value |
|---|---|---|---|---|---|
| Cholesterol (mg/dL) | 155 | 193 (154, 216) | 188 (160, 233) | 0.58 | 0.60 |
| Triglycerides (mg/dL) | 155 | 168 (126, 232) | 177 (140, 224) | 0.60 | 0.60 |
| Body mass index (kg/m2) | 154 | 35.0 (31.4, 40.6) | 33.7 (30.7, 36.9) | 0.084 | 0.17 |
| Abdominal circumference (cm) | 154 | 118 (111, 126) | 118 (108, 126) | 0.44 | 0.60 |
| CAP (dB/m) | 103 | 359 (323, 384) | 317 (286, 353) | 0.004 | 0.011 |
| Transient elastography (kPa) | 103 | 7.2 (5.9, 9.9) | 5.5 (4.3, 7.3) | <0.001 | 0.002 |
Median values (Q1, Q3) are presented for each group. p-values were obtained using the Wilcoxon rank sum test, with q-values indicating the false discovery rate for multiple testing. CAP—controlled attenuation parameter, and N represents the number of participants (total and in each group).